Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.

Björn PasternakViktor WintzellMads MelbyeBjörn EliassonAnn-Marie SvenssonStefan FranzénSoffia GudbjörnsdottirKristian HveemChristian JonassonHenrik SvanströmPeter Ueda

Published in: BMJ (Clinical research ed.) (2020)

In this analysis using nationwide data from three countries, use of SGLT2 inhibitors, compared with dipeptidyl peptidase-4 inhibitors, was associated with a significantly reduced risk of serious renal events.

Keyphrases

big data
machine learning